Skip to content
KYAN Therapeutics

KYAN Therapeutics

AI Platform for Combination Therapy, Clinical Stratification and Drug/Dose Recommendation

  • Home
  • About Us
  • Media Releases
  • Technology
  • Publications
  • Contact Us

Publications

2020

Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma
Experimental Hematology & Oncology

Artificial intelligence in cancer therapy
Science

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
Blood Cancer Journal 

2019

Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection
Advanced Therapeutics

Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine
SLAS Technology​

2018

Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Advanced Therapeutics

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
Science Translational Medicine

2017

Optimizing Combination Therapy for Acute Lymphoblastic Leukemia Using a Phenotypic Personalized Medicine Digital Health Platform: Retrospective Optimization Individualizes Patient Regimens to Maximize Efficacy and Safety
SLAS Technology

2016

Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform
Science Translational Medicine

Diamonds, Digital Health, and Drug Development: Optimizing Combinatorial Nanomedicine
ACS Nano

Copyright © 2021 KYAN Therapeutics, Inc. All Rights Reserved.
  • LinkedIn